Clinical Trials Logo

Filter by:
NCT ID: NCT00036205 Terminated - Parkinson Disease Clinical Trials

Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease

Start date: August 2000
Phase: Phase 3
Study type: Interventional

The primary objective is to assess the long term safety and tolerability of sumanirole as measured by safety labs, ECG monitoring, vital signs, and adverse event reports in subjects with Parkinson's Disease who participated in previous sumanirole studies.

NCT ID: NCT00036088 Completed - Schizophrenia Clinical Trials

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Start date: August 2001
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

NCT ID: NCT00035425 Completed - Febrile Neutropenia Clinical Trials

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

Start date: November 2001
Phase: Phase 3
Study type: Interventional

This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).

NCT ID: NCT00035035 Completed - Clinical trials for Pancreatic Neoplasms

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Start date: n/a
Phase: Phase 3
Study type: Interventional

Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.

NCT ID: NCT00034268 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purposes of this study are to determine: 1. If treatment with LY900003 plus gemcitabine and cisplatin can help you live longer, compared with gemcitabine and cisplatin alone. 2. The safety of LY900003 plus gemcitabine and cisplatin and any side effects that might be associated with the combination of these three drugs. 3. Whether LY900003 plus gemcitabine and cisplatin can make your tumor smaller or disappear, and for how long, compared with gemcitabine and cisplatin alone. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate LY900003 plus gemcitabine and cisplatin for other possible uses or for other medical or scientific purposes other than those currently proposed. LY900003 may not add any benefit to gemcitabine plus cisplatin.

NCT ID: NCT00034125 Completed - Breast Neoplasms Clinical Trials

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Start date: n/a
Phase: Phase 3
Study type: Interventional

To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.

NCT ID: NCT00029848 Completed - Obesity Clinical Trials

Obese Patients With Type 2 Diabetes

RIO-Diabetes
Start date: October 2001
Phase: Phase 3
Study type: Interventional

To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes

NCT ID: NCT00028301 Completed - HIV Infections Clinical Trials

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

Start date: February 2001
Phase: Phase 3
Study type: Interventional

This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.

NCT ID: NCT00027352 Completed - HIV Infections Clinical Trials

A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)

Start date: n/a
Phase: N/A
Study type: Observational

The purpose of this study is to compare two ways of using anti-HIV drugs to help health care providers and patients decide how to best use anti-HIV treatments over many years. Many health care providers now treat patients with daily drugs to keep the viral load as low as possible. This approach helps patients with CD4 counts less than 200-250 cells/mm3 live longer without serious diseases. But it is not known if this is the best way to treat patients with higher CD4 counts. There is information suggesting that these patients may be able to wait to use anti-HIV drugs while CD4 counts are above 250 cells/mm3. Because this study will be carried out over several years, it will provide information on the long-term advantages and disadvantages of these two treatment strategies.

NCT ID: NCT00026338 Completed - Pancreatic Cancer Clinical Trials

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Start date: October 29, 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer.